Study on Safety and Performance of AdvanCore Bone Void Filler

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The objective of this study is to evaluate the safety and performance of AdvanCore implantable bone graft through a 12-month follow-up period in a prospective, parallel-group design, non-controlled, open label, multi-center and real-world setting study. This study is intended to satisfy post-market clinical follow-up requirements of CE Mark in Europe.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult subjects ≥ 18 years old, male or female.

• Subjects who are eligible for a bone grafting/bone void filler procedure.

• Subjects with bone lesions beyond the limits of the bone's self-healing ability.

• Subjects, and/or an authorized representative, who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center.

• Subjects with only one fracture susceptible to treatment with an AdvanCore implant.

Locations
Other Locations
Portugal
Unidade Local de Saúde do Alto Ave
RECRUITING
Guimarães
Unidade Local de Saúde de Trás-os-Montes e Alto Douro
RECRUITING
Lordelo
Unidade Local de Saúde de São João
NOT_YET_RECRUITING
Porto
Unidade Local de Saúde do Médio Tejo
NOT_YET_RECRUITING
Tomar
Contact Information
Primary
Francisca C Costa
f.costa@artursalgado.pt
+351253794649
Time Frame
Start Date: 2025-05-29
Estimated Completion Date: 2026-10
Participants
Target number of participants: 190
Treatments
Experimental: Long-bone injuries
Group formed by subjects with long-bone injuries treated using AdvanCore blocks, wedges, or granules.
Experimental: Spine injuries
Group formed by subjects with spine injuries treated using AdvanCore granules.
Experimental: Maxillofacial injuries
Group formed by subjects with maxillofacial injuries treated using AdvanCore granules.
Related Therapeutic Areas
Sponsors
Leads: Artur Salgado SA
Collaborators: NAMSA

This content was sourced from clinicaltrials.gov